Trevena Announces Partial Exercise of Underwriters' Overallotment Option

By: via Benzinga
Trevena (NASDAQ: TRVN), a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.